CSIMarket
 


Vir Biotechnology Inc   (VIR)
Other Ticker:  
 

Vir Biotechnology Inc 's Tangible Leverage Ratio

VIR's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to repayements of liabilities of -11.08% Vir Biotechnology Inc improved Tangible Leverage Ratio in forth quarter 2023 to 0.21, below the company's average Tangible Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the forth quarter 2023, 7 other companies have achieved lower Tangible Leverage Ratio than Vir Biotechnology Inc in the IV Quarter 2023. While Tangible Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 135, from total ranking in the third quarter 2023 at 502 .

Explain Tangible Leverage Ratio?
What is VIR Market Share?
What are VIR´s Total Liabilities?


VIR Tangible Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Tangible Equity Change -23.54 % -22.25 % -7.06 % -1.52 % 46.8 %
Y / Y Total Liabilities Change -54.59 % -32.28 % -16.34 % -5.4 % 95.49 %
Tangible Leverage Ratio MRQ 0.21 0.23 0.25 0.36 0.36
VIR's Total Ranking # 135 # 502 # 598 # 763 # 203
Seq. Tangible Equity Change -5.02 % -7.64 % -7.99 % -5.28 % -3.42 %
Seq. Total Liabilities Change -11.08 % -14.72 % -37.62 % -4 % 32.6 %



Tangible Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 8
Healthcare Sector # 44
Overall Market # 135


Tangible Leverage Ratio Statistics
High Average Low
0.64 0.28 0.14
(Mar 31 2021)   (Sep 30 2020)




Financial Statements
Vir Biotechnology Inc 's Tangible Equity $ 1,551 Millions Visit VIR's Balance sheet
Vir Biotechnology Inc 's Total Liabilities $ 329 Millions Visit VIR's Balance sheet
Source of VIR's Sales Visit VIR's Sales by Geography


Cumulative Vir Biotechnology Inc 's Tangible Leverage Ratio

VIR's Tangible Leverage Ratio for the trailling 12 Months

VIR Tangible Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Tangible Equity TTM Growth -23.54 % -22.25 % -7.06 % -1.52 % 46.8 %
Y / Y Total Liabilities TTM Growth -54.59 % -32.28 % -16.34 % -5.4 % 95.49 %
Tangible Leverage Ratio TTM 0.27 0.3 0.31 0.31 0.32
Total Ranking TTM # # # # #
Seq. Tangible Equity TTM Growth -5.02 % -7.64 % -7.99 % -5.28 % -3.42 %
Seq. Total Liabilities TTM Growth -11.08 % -14.72 % -37.62 % -4 % 32.6 %


On the trailing twelve months basis Due to repayements of liabilities of -11.08% Vir Biotechnology Inc decreased Tangible Leverage Ratio in the 12 months ending in IV Quarter 2023 to 0.27, below the company's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 7, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Vir Biotechnology Inc . While Tangible Leverage Ratio total ranking has improved so far to 113, from total ranking in previous 12 month period at 314.

Explain Tangible Leverage Ratio?
What is VIR Market Share?
What are VIR´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 8
Healthcare Sector # 44
Within the Market # 135


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.64 0.28 0.14
(Mar 31 2021)   (Sep 30 2020)




Companies with similar Tangible Leverage Ratio in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Tangible Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Tangible Equity
Vericel Corporation  0.58 $ 127.705  Millions$ 219.077  Millions
C4 Therapeutics Inc   0.53 $ 130.337  Millions$ 246.114  Millions
Iovance Biotherapeutics Inc   0.53 $ 187.961  Millions$ 355.355  Millions
Immunocore Holdings Plc  0.52 $ 192.137  Millions$ 368.843  Millions
Recursion Pharmaceuticals Inc   0.51 $ 190.263  Millions$ 374.937  Millions
Neurocrine Biosciences Inc   0.46 $ 1,019.400  Millions$ 2,196.500  Millions
Prime Medicine Inc   0.46 $ 60.780  Millions$ 133.071  Millions
Editas Medicine Inc   0.43 $ 150.056  Millions$ 349.097  Millions
Sophia Genetics Sa  0.36 $ 54.714  Millions$ 151.442  Millions
Black Diamond Therapeutics Inc   0.36 $ 41.831  Millions$ 116.736  Millions
Tarsus Pharmaceuticals Inc   0.35 $ 68.503  Millions$ 193.121  Millions
Passage Bio inc   0.35 $ 39.262  Millions$ 111.283  Millions
Moderna Inc   0.33 $ 4,572.000  Millions$ 13,854.000  Millions
Scholar Rock Holding Corp  0.33 $ 74.017  Millions$ 225.218  Millions
Twist Bioscience Corporation  0.32 $ 142.773  Millions$ 451.041  Millions
Exelixis Inc   0.31 $ 678.445  Millions$ 2,200.228  Millions
Adverum Biotechnologies Inc   0.30 $ 24.914  Millions$ 83.469  Millions
Dbv Technologies S a   0.27 $ 37.696  Millions$ 140.129  Millions
Replimune Group Inc   0.26 $ 111.393  Millions$ 421.537  Millions
Allogene Therapeutics inc   0.25 $ 130.604  Millions$ 512.233  Millions
Vir Biotechnology Inc   0.21 $ 328.824  Millions$ 1,550.734  Millions
Anavex Life Sciences Corp   0.18 $ 24.073  Millions$ 135.575  Millions
Caribou Biosciences Inc   0.17 $ 63.808  Millions$ 368.401  Millions
Voyager Therapeutics Inc   0.17 $ 39.721  Millions$ 236.320  Millions
Fresh Tracks Therapeutics Inc   0.17 $ 1.656  Millions$ 9.930  Millions
Acumen Pharmaceuticals Inc   0.16 $ 43.152  Millions$ 266.973  Millions
Springworks Therapeutics Inc   0.16 $ 99.569  Millions$ 626.219  Millions
Biontech Se  0.14 $ 3,091.648  Millions$ 22,269.408  Millions
Molecular Partners Ag  0.12 $ 21.923  Millions$ 176.429  Millions
Denali Therapeutics Inc   0.12 $ 122.963  Millions$ 1,030.954  Millions

Date modified: 2024-02-27T10:49:35+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com